Pfizer (PFE) Looks to Remove 'Black Box' Warning from Chantix
Get Alerts PFE Hot Sheet
Price: $26.27 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.4%
Revenue Growth %: -23.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.4%
Revenue Growth %: -23.7%
Join SI Premium – FREE
Pfizer (NYSE: PFE) will request that U.S. regulators remove a black box
warning from its anti-smoking medication, Chantix.
According to reports Wednesday, the U.S. FDA recently updated labeling on Chantix which includes data from a number of recent studies that found little to no evidence of psychiatric problems or suicidal tendencies in patients taking the tablet.
The FDA will convene a panel in October to review Chantix's risks at the request of Pfizer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer Declares Second-Quarter 2024 Dividend
- BioNano Genomics (BNGO) Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
- Altamira Therapeutics (CYTO) Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!